Tamoxifen and raloxifene have also been shown to inhibit the growth of ERα-negative/ERβ-positive bladder cancer cells and their xenograft tumors [44,51,52,53], while raloxifene failed to significantly affect that of ERα/ERβ knockdown lines [51]. Here, ESR1 is linked to urinary bladder carcinoma.